Clinical Pathways

With the risk of upgrade of flat epithelial atypia to malignancy is low, surveillance rather than surgery is a reasonable option for patients, according to a study.

The FDA has granted Priority Review designation for Eli Lilly and Company’s New Drug Application (NDA) for Verzenio (abemaciclib), a cyclindependent kinase 4 and 6 inhibitor for metastatic breast cancer. The decision was based on the MONARCH 3 study, which examined abemaciclib as an initial endocrine-based therapy.

Results of the 70-gene signature assay strongly influence physician's treatment recomendations for patients with early breast cancer who were classified as intermediate risk by the 21-gene assay.

After a study reported that physicians who authored dermatology clinical guidelines didn't always fully disclose financial conflicts of interest, the American Academy of Dermatology urged the public to view the findings with caution.

October is breast cancer awareness month, and as September ended, a new treatment received the FDA’s approval for advanced breast cancer and another was granted priority review for the adjuvant treatment of early breast cancer.

A new paper in JCO Precision Oncology evaluated the impact of the support provided by a decision support team on clinical decision making and trial enrollment.

Physicians across different institutes who have been involved in clinical trials of chimeric antigen receptor (CAR) T cells in B-cell lymphomas have developed a guideline for monitoring and managing the symptoms associated with this treatment.

Cabazitaxel can now be used at a dose of 20 mg/m2 every 3 weeks in combination with prednisone in patients with metastatic castration-resistant prostate cancer who have received a docetaxel-based treatment regimen.

Patients with relapsed follicular lymphoma now have a new treatment option: copanlisib, a kinase inhibitor that was recently approved through the FDA’s accelerated approval process.

The FDA has approved bevacizumab-awwb (Mvasi) as a treatment for multiple cancers. The drug has been approved as a biosimilar to its reference biologic, bevacizumab (Avastin), but it has not been approved as an interchangeable product.

In recent years, testing for the BRCA1/2 gene mutations has increased among women in both metropolitan and nonmetropolitan areas, helping to drastically reduce the gap in testing rates between the groups.

According to a new study published in Cancer, an annual screening mammogram starting at age 40 has the greatest impact on reducing mortality.

Value frameworks are tools used to clarify cost-benefit tradeoffs in healthcare decisions, which means they can look very different depending on their intended audience, according to Clifford Goodman, PhD, moderator at the ACO Coalition spring live meeting in Scottsdale, Arizona, and senior vice president and director at the Center for Comparative Effectiveness Research at the Lewin Group.

A new liquid biopsy test that uses flow cytometry to detect cancer cells has been FDA approved for chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms.

Tort reform has been on doctors' wish lists for decades. Supporters of reform say it would reduce frivolous claims and stop doctors from practicing defensive medicine, while some consumer groups say doctors should not be insulated from liability for egregious errors.

On June 14, 2017, The Institute for Clinical and Economic Review (ICER) added a “New Evidence Update” to the 2015 review of the comparative clinical effectiveness and value of PCSK9 inhibitors for management of high cholesterol.

Updated results from the POLLUX and CASTOR trials, presented at the 2017 American Society of Clinical Oncology Annual Meeting, have found that including daratumumab in standard-of-care regimens prolonged progression-free survival (PFS) and improved the depth of response, independent of the patients’ cytogenetic risk.

Patients with metastatic non-small cell lung cancer (NSCLC) who have a rearrangement in the anaplastic lymphoma kinase (ALK) gene now have a first-line option: ceritinib.

A year-long collaboration between a health consultancy and a think tank has resulted in the first draft of a framework that considers the value of healthcare services from the patient’s perspective.

A new study indicates that a technology-based intervention could help patients make informed decisions about cancer screening.